Compare Amylx Pharmaceuticals Inc (AMLX) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Oatly Group AB - ADR — how do they compare? Amylx Pharmaceuticals Inc trades at $23.93 (market cap $2.64B), while Oatly Group AB - ADR trades at $13.16 (market cap $415.98M). The key difference: Amylx Pharmaceuticals Inc is far larger — about 6.3× Oatly Group AB - ADR's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Oatly Group AB - ADR nearer its low. Which is the better fit depends on your goals.
| AMLX | OTLY | |
|---|---|---|
Market Cap | $2.64B | $415.98M |
Sector | Health | Consumer Staples |
52-Week High | $24.19 | $18.54 |
52-Week Low | $7.82 | $8.03 |
Enterprise Value | $2.39B | $920.39M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
OTLY trades at $13.12, down 4.37% today, but maintains a bullish technical outlook with strong moving average and oscillator signals. The company reported Q2 2026 revenue growth and raised full-year guidance, showing progress toward profitability with improving gross margins. However, negative net income and cash flow challenges persist, with the stock trading at a low P/S ratio of 0.44 but elevated P/B of 79.9.
The investment case hinges on OTLY's operational turnaround and revenue acceleration, but significant risks remain from cash burn and high debt levels. Analyst sentiment is mixed with 44% buy ratings, while technical indicators suggest near-term support at $13. The path to sustainable profitability remains the key catalyst for stock appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
